Simplify Asset Management Inc. Invests $1.42 Million in Insmed Incorporated (NASDAQ:INSM)

Simplify Asset Management Inc. bought a new position in Insmed Incorporated (NASDAQ:INSM) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 20,520 shares of the biopharmaceutical company’s stock, valued at approximately $1,417,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC raised its holdings in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC raised its holdings in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares during the period. Spire Wealth Management purchased a new position in Insmed in the fourth quarter valued at approximately $47,000. Smartleaf Asset Management LLC lifted its position in Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in Insmed during the fourth quarter worth approximately $86,000.

Insmed Stock Performance

Shares of Insmed stock opened at $79.92 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The firm’s 50-day simple moving average is $77.43 and its 200-day simple moving average is $73.80. The firm has a market cap of $14.47 billion, a PE ratio of -14.30 and a beta of 1.28.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Equities analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on INSM shares. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Royal Bank of Canada restated an “outperform” rating and set a $100.00 price objective on shares of Insmed in a research note on Wednesday. Guggenheim reiterated a “buy” rating and issued a $101.00 target price on shares of Insmed in a research note on Tuesday, February 25th. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, Morgan Stanley increased their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and an average price target of $94.00.

Insider Buying and Selling

In related news, insider Martina M.D. Flammer sold 3,344 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the sale, the insider now owns 102,766 shares of the company’s stock, valued at $6,773,307.06. This represents a 3.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the completion of the transaction, the chief executive officer now directly owns 384,960 shares in the company, valued at $26,885,606.40. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 550,957 shares of company stock worth $42,992,528 over the last ninety days. 4.60% of the stock is owned by insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.